Next, we used three inhibitors (Dinaciclib, Alisertib, or Barasertib), which targeted the top candidate hits (CDK members, AURKA, or AURKB) to validate the screen results in multiple osteosarcoma cell lines. The gene discussed is AURKA; the disease is osteosarcoma.